Exagen Inc. (NASDAQ: XGN) lifts Q2 2026 revenue to $19.9M
Exagen Inc. reported a significant increase in Q2 2026 revenue to $19.9 million, up from $17.2 million a year earlier, primarily driven by its AVISE® CTD autoimmune diagnostic test. The company narrowed its net loss to $3.2 million and improved its operating loss to …